

1 Declining SARS-CoV-2 PCR sensitivity
2 with time and dependence on clinical
3 features: consequences for control

*Authors: B.J.M. Bergmans¹, C.B.E.M. Reusken², A.J.G. van Oudheusden¹, G.J. Godeke², A.A. Bonačić
Marinović², E. de Vries^{1,3}, Y.C.M. Kluiters-de Hingh¹, R. Vingerhoets¹, M.A.H. Berrevoets¹, J.J. Verweij¹, A.E.
Nieman¹, J. Reimerink², J.L. Murk¹, A.N. Swart^{2*}*

Affiliations:

1 Laboratory of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.

2 Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

3 Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands.

** Correspondence to: A.N. Swart, arno.swart@rivm.nl*

4 **Abstract**

5 Real-time reverse transcription-polymerase chain reaction (RT-PCR) on upper respiratory tract
6 (URT) samples is the primary method to diagnose SARS-CoV-2 infections and guide public
7 health measures, with a supportive role for serology. However, the clinical sensitivity of RT-PCR
8 remains uncertain. In the present study, Bayesian statistical modeling was used to
9 retrospectively determine the sensitivity of RT-PCR using SARS-CoV-2 serology in 644 COVID-19-
10 suspected patients with varying degrees of disease severity and duration. The sensitivity of RT-
11 PCR ranged between 79-95%; while increasing with disease severity, it decreased rapidly over
12 time in mild COVID-19 cases. Negative URT RT-PCR results should therefore be interpreted in
13 the context of clinical characteristics, especially with regard to containment of viral
14 transmission based on the ‘test, trace and isolate’ principle.

Introduction

COVID-19 is diagnosed primarily by testing upper respiratory tract (URT) samples with real-time reverse transcription-polymerase chain reaction (RT-PCR)(1). Experience with nucleic acid amplification tests for other respiratory viruses, such as influenza virus, granted a high level of confidence in the clinical sensitivity of these types of assays(2). Early in the SARS-CoV-2 pandemic, however, Chinese clinicians already reported substantial numbers of negative tests of URT samples from patients with a high level of clinical suspicion for COVID-19(3, 4). Frequent false-negatives were later also reported by other physicians worldwide(5, 6) and were indicated to significantly complicate healthcare organization, hospital admission and isolation capacity (7, 8).

In several systematic reviews, the false-negative rate of RT-PCR was calculated to range between 22-66%, depending on symptom duration(9, 10). It is not known whether false-negatives were due to methodological problems, such as sampling error, suboptimal handling of samples or suboptimal assay design, or if they reflect a biological feature of SARS-CoV-2 infections. Clinical samples of lower respiratory tract material such as sputum or broncho-alveolar lavage fluid (BALF) appeared to yield significantly lower false negative rates than URT samples in patients with COVID-19 pneumonia (3, 11, 12). However, only 13-30% of patients produce sputum(7) and obtaining BALF is often impossible due to severe respiratory distress, or not indicated due to mild disease. URT samples are therefore the preferred and most feasible sample type. Estimates of sensitivity are further complicated by the lack of a reliable

37 gold standard. Although imaging techniques may aid in the diagnosis of COVID-19(13, 14),
38 their sensitivity and specificity are insufficient to be used as such.

39

40 Although complex, it is crucial to reliably assess the sensitivity of RT-PCR in different
41 clinical cohorts as RT-PCR is the foundation for test, trace and isolation policies that are the
42 cornerstone of worldwide pandemic control efforts. Highly sensitive and specific antibody
43 assays are important tools to support patient diagnostics at a later stage of the disease. We
44 postulate these can also be used to investigate the clinical sensitivity of RT-PCR. In the
45 present study, Bayesian statistical modeling was used to retrospectively determine the
46 clinical sensitivity of RT-PCR in URT-samples from a large cohort of COVID-19-suspected
47 patients with varying degrees of disease severity and symptom duration using serology assays.

Results


48
49 In the study period, 644 patients (>18 years of age) that presented at our hospital with clinically
50 suspected COVID-19 were tested for SARS-CoV-2 by RT-PCR on URT samples. URT material was
51 obtained by combined swabbing of subsequently oropharynx (OP) and nasopharynx (NP),
52 using the same swab, to increase sensitivity and reduce the logistic and resource burden(15). In
53 addition, serum samples were taken after a minimum of 12 days post disease onset whenever
54 possible, to determine if specific antibodies to SARS-CoV-2 had developed. Samples were
55 obtained either through collection of left-over serum, taken for other purposes (N=109) or by
56 asking patients to have a blood sample taken for the purpose of this study (N= 141). In total,
57 sera from 250 patients were obtained and analyzed for the presence of SARS-CoV-2 specific
58 antibodies (Table 1, Fig. 1). To this goal, two independent tests were used; an in-house
59 developed protein micro-array based on SARS-CoV-2 S1 and N proteins (PMA (16, 17)) and the
60 Wantai total antibody ELISA based on the RBD-domain of S1 (Beijing Wantai Biological
61 Pharmacy Enterprise, Beijing, China; Cat # WS1096). The manufacturers of the Wantai assay
62 recommend index values of 1.1 and higher as evidence for the presence of specific antibodies.
63 However, we observed that at this cut-off value, several RT-PCR confirmed patients scored
64 negative and a cut-off of 0.25 was calculated to be more appropriate in our cohort (Fig. 2,
65 Supplementary Text). The rightmost panel of this figure gives quantitative evidence. The
66 histogram is scaled to 100% height per bar, and colored according to percentage of PCR positive
67 (purple) and negative (yellow) status of the patients. Clearly, using the manufacturer's cut-off,
68 many positives would be to the left of the cut-off and would score false-negative in the Wantai
69 test.

	Serum collected	No serum collected	p	Total
	(N=250)	(N=394)		(N=644)
Age, mean (SD), years	64.5 (14.38)	67.9 (16.33)	0.007	66.6 (15.7)
Female, N (%)	116 (46.4%)	148 (37.6%)	0.026	264 (41%)
Immunocompromised, N (%)	37 (14.8%)	36 (9.12%)	0.027	73 (11.3%)
Interval symptom onset and URT-swab collection, mean (SD), days	8.25 (6.68)	7.49 (7.54)	0.192	7,78 (7.2)
Disease severity categories				
1, outpatients, N (%)	58 (23.2%)	67 (17.0%)	0.148	125 (19.4%)
2, hospitalized, non-ICU, N (%)	162 (64.8%)	273 (69.3%)		435 (67.5%)
3, ICU, N (%)	30 (12.0%)	54 (13.7%)		84 (13%)
Deceased, N (%)	16 (6.4%)	120 (30.5%)	<0.001	136 (21.1%)
First URT-swab positive (N/N total)	109 (43.6%)	195 (49.5%)	0.144	304 (47.2%)
Ct-value (first URT-swab)	28.7 (6.59)	28.5 (5.63)	0.795	28.5 (5.99)
RT-PCR positive (any sample, total), N (%)	123 (49.2%)	216 (54.8%)	0.164	339 (52.6%)
Additional samples in first URT-swab negative patients				
Second URT-swab positive (N/N total)	1/38 (2.6%)	9/51 (17.6%)		10/89 (11.2%)
Sputum positive (N/N total)	2/9 (22.2%)	4/19 (21.1%)		6/28 (21.4%)
Feces positive (N/N total)	11/29 (37.8%)	12/29 (41.4%)		23/58 (39.6%)
Interval symptom onset and	26.7 (10.1)	NA		26.7 (10.1)

serum collection, mean (SD), days				
Wantai ab index value (out of N=250)	10.38 (10.1)	NA		10.38 (10.1)
Wantai ab positive (out of N=250)	155 (62.0%)	NA		155 (62.0%)
Ct-value, cycle threshold value; ICU, intensive care unit; SD, standard deviation; URT, upper respiratory tract; RT-PCR, reverse-transcriptase polymerase chain reaction				

70


Table 1. Cohort baseline characteristics



71

72

Figure 1 Patient cohort flow-diagram




73

74 *Figure 2. a) Histogram of Wantai total antibody index values on a logarithmic scale. The red vertical line indicates the*
75 *manufacturer's cut-off value, the green vertical line our adapted cut-off value. b) Percentage of PCR-positivity within Wantai*
76 *total antibody index values. The red vertical line indicates the manufacturer's cut-off value, the green vertical line our adapted*
77 *cut-off value.*

78 To investigate the sensitivity of RT-PCR on combined OP/NP swabs in clinically suspected
79 COVID-19 patients we applied Bayesian modeling, taking into account all test outcomes at the
80 individual level, without resort to a putative 'gold standard'. To this end, we exploit that
81 patients received multiple tests, combined with an assumption of perfect specificity, which
82 implies that a single positive test (either ELISA, microarray, or RT-PCR) indicates a
83 positive patient. Perfect clinical specificity can be justified from the high analytical
84 specificity and the fact that patients were clinically diagnosed with COVID-19 symptoms

85 (coughing, sneezing, dyspnea, rhinitis, fever or diarrhea, see Materials and Methods). URT-
86 RT-PCR sensitivity varied according to disease severity: for outpatients, 79% (57%-99%
87 Bayesian credible interval (CI)), for patients admitted to a non-ICU hospital ward 86% (77-
88 95 CI), and for patients admitted to ICU 95% (83-1.00 CI) (Fig. 3, Table S1). URT-RT-
89 PCR sensitivity was higher in males than in females (91% vs 80%), higher in deceased than
90 in non-deceased patients (95% vs 83%) and higher in immunocompromised than in
91 immunocompetent patients (93% vs 85%) (Fig. S1, Table S1).




92

93 *Figure 3 a) Posterior uncertainty distributions of the sensitivities for the microarray assays, serology and RT-PCR assay. Colors*
94 *indicate severity category. b) Prevalence estimates by severity category. Legend: ICU, Intensive Care Unit; OUP, outpatients;*
95 *WARD, non-ICU hospitalized patients; EC50_CoV-N, SARS-CoV-2 N protein microarray; EC50_CoV-S1, SARS-CoV-2 S1 protein*
96 *microarray; serum_our, Wantai serology using cut-off value of 0.25; PCR, polymerase-chain reaction*


97 For each disease severity category, URT RT-PCR cycle threshold (Ct)-values displayed an
98 increasing trend by number of days since symptom onset, reflecting a decreasing viral load
99 in time, albeit with considerable inter-individual variation (Fig. 4, Table S2). Ct-values of
100 outpatients were generally higher, even close to symptom onset, and increased rapidly
101 compared to Ct-values of hospitalized patients. Ct-values were not significantly different

102 between males and females, between immunocompromised and immunocompetent patients,
103 or between deceased and non-deceased patients (Fig. S2, Table S2). In patients admitted to a
104 regular ward, URT RT-PCR retained its sensitivity up to at least three weeks post symptom
105 onset (Fig. 5). Clearly, RT-PCR on IC and in-hospital patients retains its initial sensitivity
106 for a prolonged period of time (approximately 15 and 20 days respectively). However, the
107 point of decline is highly uncertain, due to the absence of patient material longer after onset
108 of symptoms. Therefore, conclusions on the time of decline of sensitivity should not be
109 drawn for IC and in-hospital patients. In contrast, outpatients do show a marked decrease of
110 sensitivity over time, with lower uncertainty: sensitivity could be halved already within
111 three weeks. Sensitivities according to sex, mortality and immunosuppression remained
112 stable during at least three weeks post symptom onset (Fig. S3).



113

114 *Figure 4. Linear increase of Ct-value in relation to days since onset of symptoms across different disease severity categories. The*
115 *shaded band indicates 95% Bayesian credible interval. The dots are the original data. Dots positioned at a Ct of 50 were right-*
116 *censored in the inflated model (i.e. count as either above 50 or a negative individual). Abbreviations: ICU, Intensive Care Unit;*
117 *OUTP, outpatients; WARD, non-ICU hospitalized patients; ct, Ct-value*



118

119 *Figure 5. Modeled sensitivities as a function of days since onset of symptoms. Panels and shading indicate disease severity. The*
120 *bands indicate 95% Bayesian credible interval, and black dots an estimate of sensitivity directly from the original data, by*
121 *assuming Wantai serology as the gold standard. Abbreviations: ICU, Intensive Care Unit; OUTP, outpatients; WARD, non-ICU*
122 *hospitalized patients.*

123 COVID-19-suspected patients with a negative URT RT-PCR and without alternative
124 diagnosis were frequently retested for SARS-CoV-2 after resampling. This increased the
125 total number of RT-PCR-confirmed patients with 35 (Table 1). Repeated URT-swab was
126 most commonly used, but had the least added value (10/89, 11.2% positive). Feces
127 generated the most additional positive results (23/58, 39.6%), followed by sputum (6/28,
128 21.4%). Note that these tests were not included in the Bayesian sensitivity analysis, due to
129 their dependence on the outcome of the initial URT RT-PCR (see Supplementary Text).

130

131 Serum samples were analyzed for SARS-CoV-2 antibodies by ELISA and PMA. Bayesian
132 modelling revealed an overall sensitivity of >94% for both ELISA and PMA, which did not
133 change significantly according to disease severity category, sex or mortality (Fig. 2, Table
134 S1). The sensitivity of antibody assays was lower in immunocompromised patients (82-92%,
135 Table S1) and this was the only group in which antibody assays had a lower sensitivity
136 compared to UTR RT-PCR. The ELISA and PMA results were discrepant in only four of 250
137 sera (Table S3). All four patients tested RT-PCR positive in URT-swab, and three out of four
138 were immunocompromised.

139 Discussion

140 An accurate assessment of the clinical sensitivity of diagnostic tools, in particular of RT-PCR on
141 URT samples on which global test, trace and isolate strategies are based(18), is an absolute
142 requisite for good patient care and adequate infection risk management. We observed a
143 decrease in sensitivity with decreasing disease severity, an increase in sensitivity in
144 immunocompromised patients and a rapid decline of sensitivity in time post onset of
145 symptoms, but only in outpatients. In our study, 5-14% of hospitalized COVID-19 cases and 21%
146 of outpatients tested negative in URT-PCR. This finding is in contrast with local practice and
147 guidelines, which are often based on the assumption of near-perfect sensitivity(19).

148

149 Frequent false-negatives have been consistently reported in several different countries since
150 the onset of the pandemic. The analytical sensitivity of PCRs generally approaches 100%, which
151 means tests are able to detect a single viral genome copy in the reaction volume(20–23), the

152 clinical sensitivity may be substantially lower, due to low quality of samples, presence of
153 inhibiting factors, suboptimal pre-analytic processing or specific biologic features of the viral
154 infection. If one assumes infection of the URT always occurs in SARS-CoV-2 infected persons, a
155 negative URT RT-PCR could be the result of localized early clearance of the virus or low levels of
156 local viral replication. The localized clearance would then have different kinetics than the rate
157 of viral load decline we measured in this study. Alternatively, the possibility should be
158 considered that the URT of these patients was not infected and infection can remain more
159 localized (e.g. to the trachea / lower respiratory tract)(24) . As can be expected, RT-PCR
160 sensitivity of URT correlates with the SARS-CoV-2 RNA load in these samples. The increase of
161 mean Ct-value over time was significantly slower in hospitalized patients compared to
162 outpatients, which explains why the sensitivity of RT-PCR on URT samples decreased more
163 rapidly in cases with mild infections than in hospitalized patients and suggests hospitalized
164 patients have difficulties clearing the virus. In our cohort, immunocompromised patients were
165 the only category in which the sensitivity of serology was lower (PMA), or comparable (Wantai)
166 to URT-RT-PCR. According to the definition we used, 73 of 644 patients were
167 immunocompromised (Table S4). Most patients suffered from conditions severely affecting
168 humoral immunity or were treated by systemic immunosuppressants that inhibit antibody
169 production. This relative lack of antibody response may explain the lower sensitivity of serology
170 in this patient group, and it may clarify why relatively many immunocompromised patients'
171 Wantai results fell below the manufacturer's cut-off value. Although antibody assays were
172 shown to have high sensitivity in the rest of our cohort, their use in tracing and isolating
173 strategies is nonexistent, due to the fact that antibodies take a while to be produced and may

174 be detectable for several months after initial infection. Therefore, in order to timely diagnose
175 and quarantine COVID-19 patients, URT-PCR will continue to be used as the assay on which
176 initial decisions are based.

177

178 Our estimated URT-PCR sensitivity has important consequences for screening, treatment and
179 isolation measures in hospitals. Though a positive PCR does not necessarily signify the presence
180 of viable virus(25), sensitivities of 86-94% are not sufficient to lift isolation measures in the
181 event of a negative initial URT-PCR. In the early stages of hospital admission, clinical suspicion
182 and local COVID-19 prevalence should guide isolation and treatment decisions. Additionally,
183 timely sputum or feces sampling should take place in an effort to confirm COVID-19 diagnosis.
184 Several studies found that 30-50% of COVID-19 patients have detectable SARS-CoV-2 RNA in
185 feces (26, 27). In our study, feces yielded 3.5 times more RT-PCR-confirmed positives than
186 repeated URT-swab: 40% of additionally sampled feces tested positive, as opposed to only 11%
187 of repeated URT-swabs (Table 1).

188

189 Our findings also have ramifications for broad molecular testing in the general population, as
190 currently established across the world, based on URT-swabbing in high-throughput testing
191 lanes(28). The evidently often absent thorough epidemiological and clinical interpretation of
192 negative results in these settings, in combination with the observed low clinical sensitivity of
193 RT-PCR in the population with mild complaints that typically visit those testing sites, will lead to
194 missed cases. For example, if one assumes a sensitivity of 80% of RT-PCR for people with mild

195 symptoms in high-throughput testing lanes and where 200 of 10,000 persons with mild
196 complaints test positive, the apparent prevalence would be 2%. Using the Rogan-Gladen
197 estimator(29), the true prevalence would be $Apparent\ Prevalence/Sensitivity=2\%/80\%=2.5\%$.
198 Hence, out of the 9800 persons tested negative, 50 are expected to be false negatives, which
199 the system will fail to isolate.

200

201 In conclusion, our results show that for an accurate diagnosis based on RT-PCR test results and
202 subsequent appropriate clinical management and infection control measures, both in hospitals
203 and in public health, a thorough understanding of the clinical sensitivity of RT-PCR in URT
204 samples in clinically heterogeneous patient cohorts is necessary. The apparent lack of a high
205 clinical sensitivity of this standard diagnostic method in specific situations warrants vigilance for
206 missed cases especially in settings of high-throughput testing lanes where epidemiological and
207 clinical context are often disconnected from negative test results for final interpretation.

208 **References**

- 209 1. A. Bhimraj, R. L. Morgan, A. H. Shumaker, V. Lavergne, L. Baden, V. C. C. Cheng, K. M.
210 Edwards, R. Gandhi, W. J. Muller, J. C. O’Horo, S. Shoham, M. H. Murad, R. A. Mustafa, S.
211 Sultan, Y. Falck-Ytter, Infectious Diseases Society of America Guidelines on the Treatment
212 and Management of Patients with COVID-19. *Clin. Infect. Dis.* (2020),
213 doi:10.1093/cid/ciaa478.
- 214 2. U. Eigner, S. Reucher, N. Hefner, S. Staffa-Peichl, M. Kolb, U. Betz, M. Holfelder, G. Spier,
215 S. Pfefferle, M. Lütgehetmann, Clinical evaluation of multiplex RT-PCR assays for the
216 detection of influenza A/B and respiratory syncytial virus using a high throughput system.
217 *J. Virol. Methods.* **269**, 49–54 (2019).
- 218 3. Y. Yang, M. Yang, C. Shen, F. Wang, J. Yuan, J. Li, M. Zhang, Z. Wang, L. Xing, J. Wei, L.
219 Peng, G. Wong, H. Zheng, M. Liao, K. Feng, J. Li, Q. Yang, J. Zhao, Z. Zhang, L. Liu, Y. Liu,
220 Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis
221 and monitoring the viral shedding of 2019-nCoV infections, *medRxiv*, in press,
222 doi:10.1101/2020.02.11.20021493.
- 223 4. Z. Yongchen, H. Shen, X. Wang, X. Shi, Y. Li, J. Yan, Y. Chen, B. Gu, Different longitudinal
224 patterns of nucleic acid and serology testing results based on disease severity of COVID-
225 19 patients. *Emerg. Microbes Infect.* **9**, 833–836 (2020).
- 226 5. H. Krumholz, If you have coronavirus symptoms, assume you have the illness, even if you
227 test negative. *New York Times* (2020), pp. 3–4.

- 228 6. S. Woloshin, N. Patel, A. S. Kesselheim, False Negative Tests for SARS-CoV-2 Infection —
229 Challenges and Implications. *N. Engl. J. Med.* (2020), doi:10.1056/nejmp2015897.
- 230 7. J. L. Murk, R. van de Biggelaar, J. Stohr, J. Verweij, A. Buiting, S. Wittens, M. van Hooft, B.
231 Diederens, Y. Kluiters-de Hingh, E. Ranschaer, A. Brouwer, J. Retera, M. Verheijen, D.
232 Ramnarain, I. van Ek, J. van Oers, De eerste honderd opgenomen COVID-19-patiënten in
233 het Elisabeth-Tweesteden Ziekenhuis. *Ned. Tijdschr. Geneeskd.* **164**, 1–7 (2020).
- 234 8. C. B. Reusken, A. Buiting, C. Bleeker-Rovers, B. Diederens, M. Hooiveld, I. Friesema, M.
235 Koopmans, T. Kortbeek, S. P. M. Lutgens, A. Meijer, J. L. Murk, I. Overdeest, T.
236 Trienekens, A. Timen, W. Van Den Bijlaardt, J. Van Dissel, A. Van Gageldonk-Lafeber, D.
237 Van Der Vegt, P. C. Wever, W. Van Der Hoek, J. Kluytmans, Rapid assessment of regional
238 SARS-CoV-2 community transmission through a convenience sample of healthcare
239 workers, the Netherlands, March 2020. *Eurosurveillance.* **25**, 6–9 (2020).
- 240 9. L. M. Kucirka, S. A. Lauer, O. Laeyendecker, D. Boon, J. Lessler, Variation in False-Negative
241 Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by
242 Time Since Exposure. *Ann. Intern. Med.*, M20-1495 (2020).
- 243 10. I. Arevalo-Rodriguez, D. Buitrago-Garcia, D. Simancas-Racines, P. Zambrano-Achig, R. del
244 Campo, A. Ciapponi, O. Sued, L. Martinez-Garcia, A. Rutjes, N. Low, J. A. Perez-Molina, J.
245 Zamora, *medRxiv*, in press, doi:10.1101/2020.04.16.20066787.
- 246 11. R. Liu, H. Han, F. Liu, Z. Lv, K. Wu, Y. Liu, Y. Feng, C. Zhu, Positive rate of RT-PCR detection
247 of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to

- 248 Feb 2020. *Clin. Chim. Acta.* **505**, 172–175 (2020).
- 249 12. W. Wang, Y. Xu, R. Gao, R. Lu, K. Han, G. Wu, W. Tan, Detection of SARS-CoV-2 in
250 Different Types of Clinical Specimens. *JAMA - J. Am. Med. Assoc.* **323**, 1843–1844 (2020).
- 251 13. T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, L. Xia, Correlation of Chest
252 CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of
253 1014 Cases. *Radiology*, 200642 (2020).
- 254 14. F. Pan, T. Ye, P. Sun, S. Gui, B. Liang, L. Li, D. Zheng, J. Wang, R. L. Hesketh, L. Yang, C.
255 Zheng, Time course of lung changes at chest CT during recovery from Coronavirus
256 disease 2019 (COVID-19). *Radiology.* **295**, 715–721 (2020).
- 257 15. A. L. M. Vlek, T. S. Wesselius, R. Achterberg, S. F. T. Thijsen, Combined throat/nasal swab
258 sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling. *Eur. J. Clin. Microbiol.*
259 *Infect. Dis.* (2020), doi:10.1007/s10096-020-03972-y.
- 260 16. C. Reusken, H. Mou, G. J. Godeke, L. van der Hoek, B. Meyer, M. A. Müller, B. Haagmans,
261 R. de Sousa, N. Schuurman, U. Dittmer, P. Rottier, A. Osterhaus, C. Drosten, B. J. Bosch,
262 M. Koopmans, Specific serology for emerging human coronaviruses by protein
263 microarray. *Eurosurveillance.* **18**, 2–7 (2013).
- 264 17. M. Koopmans, E. de Bruin, G. J. Godeke, I. Friesema, R. van Gageldonk, M. Schipper, A.
265 Meijer, R. van Binnendijk, G. F. Rimmelzwaan, M. D. de Jong, A. Buisman, J. van Beek, D.
266 van de Vijver, J. Reimerink, Profiling of humoral immune responses to influenza viruses
267 by using protein microarray. *Clin. Microbiol. Infect.* **18**, 797–807 (2012).

- 268 18. WHO, Critical preparedness, readiness and response actions for COVID-19: WHO/2019-
269 nCoV/Community_Actions/2020.3, 1–3 (2020).
- 270 19. N. C. Grassly, M. Pons-salort, E. P. K. Parker, P. J. White, K. Ainslie, M. Baguelin, Report
271 16: Role of testing in COVID-19 control. *Imp. Coll. London COVID-19 response team*, 1–13
272 (2020).
- 273 20. V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D. K. W. Chu, T. Bleicker, S.
274 Brünink, J. Schneider, M. L. Schmidt, D. G. J. C. Mulders, B. L. Haagmans, B. Van Der Veer,
275 S. Van Den Brink, L. Wijsman, G. Goderski, J. L. Romette, J. Ellis, M. Zambon, M. Peiris, H.
276 Goossens, C. Reusken, M. P. G. Koopmans, C. Drosten, Detection of 2019 novel
277 coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. **25**, 1–8 (2020).
- 278 21. D. K. W. Chu, Y. Pan, S. M. S. Cheng, K. P. Y. Hui, P. Krishnan, Y. Liu, D. Y. M. Ng, C. K. C.
279 Wan, P. Yang, Q. Wang, M. Peiris, L. L. M. Poon, Molecular Diagnosis of a Novel
280 Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin. Chem.* **66**, 549–555
281 (2020).
- 282 22. P. B. van Kasteren, B. van der Veer, S. van den Brink, L. Wijsman, J. de Jonge, A. van den
283 Brandt, R. Molenkamp, C. B. E. M. Reusken, A. Meijer, Comparison of seven commercial
284 RT-PCR diagnostic kits for COVID-19. *J. Clin. Virol.* **128**, 104412 (2020).
- 285 23. A. K. Nalla, A. M. Casto, A. M. Casto, M. L. W. Huang, G. A. Perchetti, R. Sampoleo, L.
286 Shrestha, Y. Wei, H. Zhu, K. R. Jerome, K. R. Jerome, A. L. Greninger, Comparative
287 performance of SARS-CoV-2 detection assays using seven different primer-probe sets and

- 288 one assay kit. *J. Clin. Microbiol.* **58**, e00557-20 (2020).
- 289 24. Y. J. Hou, K. Okuda, C. E. Edwards, D. R. Martinez, T. Asakura, K. H. Dinnon, T. Kato, R. E.
290 Lee, B. L. Yount, T. M. Mascenik, G. Chen, K. N. Olivier, A. Ghio, L. V. Tse, S. R. Leist, L. E.
291 Gralinski, A. Schäfer, H. Dang, R. Gilmore, S. Nakano, L. Sun, M. L. Fulcher, A. Livraghi-
292 Butrico, N. I. Nicely, M. Cameron, C. Cameron, D. J. Kelvin, A. de Silva, D. M. Margolis, A.
293 Markmann, L. Bartelt, R. Zumwalt, F. J. Martinez, S. P. Salvatore, A. Borczuk, P. R. Tata, V.
294 Sontake, A. Kimple, I. Jaspers, W. K. O’Neal, S. H. Randell, R. C. Boucher, R. S. Baric, SARS-
295 CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.
296 *Cell*, S0092-8674(20)30675–9 (2020).
- 297 25. R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D.
298 Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J.
299 Schneider, R. Ehmann, K. Zwirgmaier, C. Drosten, C. Wendtner, Virological assessment of
300 hospitalized patients with COVID-2019. *Nature*. **581**, 465–469 (2020).
- 301 26. D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong, Y.
302 Zhao, Y. Li, X. Wang, Z. Peng, Clinical Characteristics of 138 Hospitalized Patients with
303 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.*
304 **323**, 1061–1069 (2020).
- 305 27. Y. Chen, L. Chen, Q. Deng, G. Zhang, K. Wu, L. Ni, Y. Yang, B. Liu, W. Wang, C. Wei, J. Yang,
306 G. Ye, Z. Cheng, The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. *J.*
307 *Med. Virol.* **92**, 833–840 (2020).

- 308 28. Government of the Netherlands, Testing for coronavirus, (available at
309 <https://www.government.nl/topics/coronavirus-covid-19/coronavirus-test>).
- 310 29. W. J. Rogan, B. Gladen, Estimating prevalence from the results of a screening test. *Am. J.*
311 *Epidemiol.* **107**, 71–76 (1978).
- 312 30. E. Van Der Vries, J. Anber, A. Van Der Linden, Y. Wu, J. Maaskant, R. Stadhouders, R. Van
313 Beek, G. Rimmelzwaan, A. Osterhaus, C. Boucher, M. Schutten, Molecular assays for
314 quantitative and qualitative detection of influenza virus and oseltamivir resistance
315 mutations. *J. Mol. Diagnostics.* 15, 347–354 (2013).
- 316 31. R. Lassaunière, A. Frische, Z. B. Harboe, A. C. Y. Nielsen, A. Fomsgaard, K. A. Krogfelt, C. S.
317 Jørgensen, medRxiv, in press, doi:10.1101/2020.04.09.20056325.
- 318 32. A. Lex, N. Gehlenborg, H. Strobel, R. Vuillemot, H. Pfister, UpSet: Visualization of
319 Intersecting Sets. *IEEE Trans. Vis. Comput. Graph.* 20, 1983–1992 (2014).
- 320 33. Z. Gu, R. Eils, M. Schlesner, Complex heatmaps reveal patterns and correlations in
321 multidimensional genomic data. *Bioinformatics.* 32, 2847–2849 (2016).
- 322 34. R Core Team, R: A language and environment for statistical computing (R Foundation for
323 Statistical Computing, Vienna, Austria, 2019; <https://www.R-project.org/>).

324

325

326

327 **Acknowledgments:** We thank BJ Bosch for providing the S1 antigen for the protein microarray
328 and H van Zundert for providing additional data on immunocompromise

329 **Funding:** This study has not received funding of any kind.

330 **Author contribution:**

331 JLM, BJMB, AEN and CBEMR conceived the project; BJMB arranged medical ethical approval,
332 BJMB, AJGvO and AEN provided recruitment of study participants, obtained metadata from
333 COVID-19 patients and obtained clinical samples; YCMK and MB provided additional clinical
334 samples; BJMB and AJGvO coordinated clinical sample processing; GJG and JR processed patient
335 samples; ANS, ABM and BJMB analyzed and interpreted data; BJMB, ANS, JLM, EdV, AEN,
336 CBEMR and JJV wrote and edited the manuscript with input from all listed authors.

337 **Competing interests:** Authors declare no competing interests.

338 **Data and materials availability:** The R script and data are available upon request from the
339 corresponding author.

340 **Ethical approval**

341 The study protocol was approved by both the institutional Science Review Board and the
342 regional Medical Ethics Committee METC Brabant (reference number NW2020-31), with a
343 waiver of informed consent for using left-over serum, drawn for other purposes than this study.
344 Informed consent was obtained from patients who were contacted to have a blood sample
345 drawn for the purpose of this study. The study was performed in accordance with the principles
346 of the Declaration of Helsinki and was not supported by grants of any kind.

347

348 **Supplementary Materials:**

349 Materials and Methods

350 Figures S1-S5

351 Tables S1-S9

352 References (30-34)